Neprilysin

Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Monday, May 3, 2021

b'NEWTON, Mass., May 3, 2021 /PRNewswire/ --Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended March 31, 2021.

Key Points: 
  • b'NEWTON, Mass., May 3, 2021 /PRNewswire/ --Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended March 31, 2021.
  • Net sales for the first quarter of 2021 were largely driven by prescription demand from both academic and community-based oncologists for patients with multiple myeloma.
  • Further, over 160 new physician prescribing accounts were added in the first quarter of 2021, which included physicians treating both myeloma and diffuse large B-cell lymphoma (DLBCL).
  • Karyopharm expects this review to be completed in the fourth quarter of 2021.\nFirst Patient Dosed in Phase 2/3 Confirmatory Study in DLBCL.

Novartis Entresto® granted expanded indication in chronic heart failure by FDA

Retrieved on: 
Tuesday, February 16, 2021

FortiHFy includes trials across the spectrum of heart failure, such as PARADIGM-HF, PIONEER-HF, TRANSITION, PROVE-HF, PARAGON-HF and PARAMOUNT.

Key Points: 
  • FortiHFy includes trials across the spectrum of heart failure, such as PARADIGM-HF, PIONEER-HF, TRANSITION, PROVE-HF, PARAGON-HF and PARAMOUNT.
  • Entresto (sacubitril/valsartan) is a prescription medicine to treat adults with long-lasting (chronic) heart failure to help reduce the risk of death and hospitalization.
  • Patients should talk to their doctor about other ways to treat heart failure if they plan to become pregnant.
  • 2010;303(21):2141-2147. doi:10.1001/jama.2010.748
    Langenickel T, Dole W. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure.

Oncopeptides will host a webcast on Wednesday, December 9th at 14:00 (CET) to provide an update regarding data presented at the ASH annual meeting

Retrieved on: 
Monday, December 7, 2020

Melflufen (INN melphalan flufenamide)is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.

Key Points: 
  • Melflufen (INN melphalan flufenamide)is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.
  • Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately hydrolyzed by peptidases to release an entrapped hydrophilic alkylator payload.
  • Aminopeptidases are overexpressed in tumor cells and are even more pronounced in advanced cancers and tumors with a high mutational burden.
  • In vitro, melflufen is 50-fold more potent in myeloma cells than the alkylator payload itself due to the increased intracellular alkylator concentration.

Oncopeptides will host a webcast on Wednesday, December 9th at 14:00 (CET) to provide an update regarding data presented at the ASH annual meeting

Retrieved on: 
Monday, December 7, 2020

Melflufen (INN melphalan flufenamide)is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.

Key Points: 
  • Melflufen (INN melphalan flufenamide)is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.
  • Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately hydrolyzed by peptidases to release an entrapped hydrophilic alkylator payload.
  • Aminopeptidases are overexpressed in tumor cells and are even more pronounced in advanced cancers and tumors with a high mutational burden.
  • In vitro, melflufen is 50-fold more potent in myeloma cells than the alkylator payload itself due to the increased intracellular alkylator concentration.

CytoDyn Completes Second Non-dilutive $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants to Help Expedite License Applications Here and Abroad and Successful COVID-19 Trials

Retrieved on: 
Wednesday, November 11, 2020

The note may be converted at the option of the investor into shares of the Companys common stock at a conversion price of $10.00 per share.

Key Points: 
  • The note may be converted at the option of the investor into shares of the Companys common stock at a conversion price of $10.00 per share.
  • CytoDyn completed its Phase 2 clinical trial (CD10) for COVID-19, a double-blinded, randomized clinical trial for mild-to-moderate patients in the U.S. which produced statistically significant results for NEWS2.
  • The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses.
  • The first indication is a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer.

Oncopeptides Announces that New Data for Melflufen is Accepted for Presentation at the Annual American Society of Hematology Meeting

Retrieved on: 
Wednesday, November 4, 2020

Melflufen (INN melphalan flufenamide)is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and releases alkylating agents into tumor cells.

Key Points: 
  • Melflufen (INN melphalan flufenamide)is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and releases alkylating agents into tumor cells.
  • Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately hydrolyzed by peptidases to release an entrapped hydrophilic alkylator payload.
  • Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases.
  • The lead product candidate melflufen, is a first in class peptide-drug conjugate that targets aminopeptidases and releases alkylating agents into tumor cells.

Oncopeptides Announces that New Data for Melflufen is Accepted for Presentation at the Annual American Society of Hematology Meeting

Retrieved on: 
Wednesday, November 4, 2020

Melflufen (INN melphalan flufenamide)is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and releases alkylating agents into tumor cells.

Key Points: 
  • Melflufen (INN melphalan flufenamide)is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and releases alkylating agents into tumor cells.
  • Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately hydrolyzed by peptidases to release an entrapped hydrophilic alkylator payload.
  • Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases.
  • The lead product candidate melflufen, is a first in class peptide-drug conjugate that targets aminopeptidases and releases alkylating agents into tumor cells.

Global Anti-Neprilysin Market to surpass US$ 1.6 billion by 2027, Says Coherent Market Insights (CMI)

Retrieved on: 
Thursday, September 10, 2020

According to Coherent Market Insights, the global anti-neprilysin market is estimated to be valued at US$ 1,160.01 million in 2020 and is expected to exhibit a CAGR of 4.6% during the forecast period (2020-2027).

Key Points: 
  • According to Coherent Market Insights, the global anti-neprilysin market is estimated to be valued at US$ 1,160.01 million in 2020 and is expected to exhibit a CAGR of 4.6% during the forecast period (2020-2027).
  • Key Trends and Analysis of the Global Anti-Neprilysin Market:
    The global anti-neprilysin market is expected to witness significant growth, owing to increasing product approvals by the regulatory bodies.
  • The increasing number of product launches is also expected to drive growth of the anti-neprilysin market over the forecast period.
  • The global anti-neprilysin market is expected to exhibit a CAGR of 4.6% during the forecast period (2020-2027), owing to increasing demand for anti-neprilysin drugs, worldwide.

FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma

Retrieved on: 
Saturday, August 29, 2020

The information in the press release is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation.

Key Points: 
  • The information in the press release is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation.
  • The information was submitted for publication, through the agency of the contact person above, on August 29, 2020 at 10.00 (CET).
  • Melflufen (INN melphalan flufenamide)is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.
  • Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately hydrolyzed by peptidases to release an entrapped hydrophilic alkylator payload.

FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma

Retrieved on: 
Saturday, August 29, 2020

The information in the press release is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation.

Key Points: 
  • The information in the press release is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation.
  • The information was submitted for publication, through the agency of the contact person above, on August 29, 2020 at 10.00 (CET).
  • Melflufen (INN melphalan flufenamide)is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.
  • Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately hydrolyzed by peptidases to release an entrapped hydrophilic alkylator payload.